UCB S.A.: Epilepsy trials

The registry lists 132 Epilepsy studies with UCB S.A. as lead sponsor. 2 are open to participants now and 90 have results posted.

Phase 1 6Phase 2 29Phase 3 74Phase 4 11No phase 14(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: BrivaracetamCompletedNCT00736931Phase 1
• Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in EpilepsyCompletedNCT00643500Phase 4
• A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in EpilepsyCompletedNCT00631150Phase 4
• S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in EpilepsyCompletedNCT00630968Phase 4
• Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial EpilepsyCompletedNCT00630630Phase 4
• Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial EpilepsyCompletedNCT00630357Phase 4
• Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.CompletedNCT00614549
• Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind MethodCompletedNCT00600509Phase 2
• Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years OldCompletedNCT00544050Phase 2
• Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of EpilepsyCompletedNCT00522522
• An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.CompletedNCT00426673Phase 1
• A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset SeizuresWithdrawnNCT00422110Phase 2/3
• Effect of Brivaracetam in Photosensitive Epileptic SubjectsCompletedNCT00401648Phase 2
• Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy PatientsCompletedNCT00394927
• UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)CompletedNCT00345475
• Cross Sectional Study to Evaluate the Acceptability of Oral Solution of LevetiracetamCompletedNCT00319605
• Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)CompletedNCT00302991
• A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset SeizuresCompletedNCT00280696Phase 3
• Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.CompletedNCT00245713Phase 4
• A Study of Brivaracetam in Subjects With Partial Onset SeizuresCompletedNCT00175929Phase 2
• Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed EpilepsyCompletedNCT00175903Phase 3
• Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.WithdrawnNCT00175864Phase 3
• Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of EpilepsyWithdrawnNCT00175851Phase 3
• Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With EpilepsyCompletedNCT00160628Phase 3
• Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic SeizuresCompletedNCT00160550Phase 3
• Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POSCompletedNCT00152373Phase 3
• Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.CompletedNCT00150787Phase 3
• Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + AdultsCompletedNCT00150774Phase 3
• Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized EpilepsyCompletedNCT00150748Phase 3
• Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From EpilepsyCompletedNCT00150735Phase 3
• SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary GeneralizationCompletedNCT00136019Phase 3
• A 19-week Cognition Study of Levetiracetam in Children With Partial Onset SeizuresCompletedNCT00105040Phase 2